Background: Basophils are thought to play pivotal roles in the pathogenesis of allergic reactions, but their roles in inflammation associated with systemic abnormalities such as metabolic disorders remain largely unknown. Advanced glycation end products (AGEs) are potentially important substances produced in high-glucose disease conditions. In this in vitro study, we investigated whether the biological functions of human basophils can be influenced by AGEs. Methods: We analyzed the effects of AGEs on various functions and markers of human basophils, including CD11b expression, apoptosis, degranulation, and cytokine production. Results: Flow cytometric analysis indicated that the level of the receptor for AGEs (RAGE) on the surface of freshly isolated basophils was very low but was clearly upregulated by IL-3. Apoptosis of basophils was induced by high concentrations of glycated albumin. Although glycated albumin failed to affect the level of surface CD11b expression or to trigger degranulation or production of IL-4 and IL-13 in basophils, it dose-dependently induced IL-6 and IL-8 secretion. Conclusions: AGEs seem to act on human basophils; they suppress the cells’ longevity but elicit secretion of inflammatory cytokines. Through these biological changes, basophils might play some roles in inflammatory conditions associated with metabolic disorders presenting elevated levels of AGEs.

Keywords:
Basophils, Advanced glycation end products, RAGE, Apoptosis
1.
Min B, Prout M, Hu-Li J, Zhu J, Jankovic D, Morgan ES, Urban JF Jr, Dvorak AM, Finkelman FD, LeGros G, Paul WE: Basophils produce IL-4 and accumulate in tissues after infection with a Th2-inducing parasite. J Exp Med 2004;200:507–517.
2.
Ohnmacht C, Voehringer D: Basophil effector function and homeostasis during helminth infection. Blood 2009;113:2816–2825.
3.
Mukai K, Matsuoka K, Taya C, Suzuki H, Yokozeki H, Nishioka K, Hirokawa K, Etori M, Yamashita M, Kubota T, Minegishi Y, Yonekawa H, Karasuyama H: Basophils play a critical role in the development of IgE-mediated chronic allergic inflammation independently of T cells and mast cells. Immunity 2005;23:191–202.
4.
Khodoun MV, Orekhova T, Potter C, Morris S, Finkelman FD: Basophils initiate IL-4 production during a memory T-dependent response. J Exp Med 2004;200:857–870.
5.
Tsujimura Y, Obata K, Mukai K, Shindou H, Yoshida M, Nishikado H, Kawano Y, Minegishi Y, Shimizu T, Karasuyama H: Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis. Immunity 2008;28:581–589.
6.
Denzel A, Maus UA, Rodriguez Gomez M, Moll C, Niedermeier M, Winter C, Maus R, Hollingshead S, Briles DE, Kunz-Schughart LA, Talke Y, Mack M: Basophils enhance immunological memory responses. Nat Immunol 2008;9:733–742.
7.
Visness CM, London SJ, Daniels JL, Kaufman JS, Yeatts KB, Siega-Riz AM, Liu AH, Calatroni A, Zeldin DC: Association of obesity with IgE levels and allergy symptoms in children and adolescents: results from the National Health and Nutrition Examination Survey 2005–2006. J Allergy Clin Immunol 2009;123:1163–1169.
8.
Al-Shawwa BA, Al-Huniti NH, DeMattia L, Gershan W: Asthma and insulin resistance in morbidly obese children and adolescents. J Asthma 2007;44:469–473.
9.
Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, Arnold B, Nawroth PP, Yan SF, D’Agati V, Schmidt AM: Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003;14:1383–1395.
10.
Yan SF, Ramasamy R, Schmidt AM: The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 2010;106:842–853.
11.
Demling N, Ehrhardt C, Kasper M, Laue M, Knels L, Rieber EP: Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res 2006;323:475–488.
12.
Suzukawa M, Iikura M, Koketsu R, Nagase H, Tamura C, Komiya A, Nakae S, Matsushima K, Ohta K, Yamamoto K, Yamaguchi M: An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol 2008;181:5981–5989.
13.
Yoshimura-Uchiyama C, Yamaguchi M, Nagase H, Fujisawa T, Ra C, Matsushima K, Iwata T, Igarashi T, Yamamoto K, Hirai K: Comparative effects of basophil-directed growth factors. Biochem Biophys Res Commun 2003;302:201–206.
14.
Iikura M, Yamaguchi M, Fujisawa T, Miyamasu M, Takaishi T, Morita Y, Iwase T, Moro I, Yamamoto K, Hirai K: Secretory IgA induces degranulation of IL-3-primed basophils. J Immunol 1998;161:1510–1515.
15.
Yoshimaru T, Suzuki Y, Inoue T, Nishida S, Ra C: Extracellular superoxide released from mitochondria mediates mast cell death by advanced glycation end products. Biochim Biophys Acta 2008;1783:2332–2343.
16.
Sick E, Brehin S, Andre P, Coupin G, Landry Y, Takeda K, Gies JP: Advanced glycation end products (ages) activate mast cells. Br J Pharmacol 2010;161:442–455.
17.
Hirai K, Miyamasu M, Takaishi T, Morita Y: Regulation of the function of eosinophils and basophils. Crit Rev Immunol 1997;17:325–352.
18.
Bochner BS, McKelvey AA, Sterbinsky SA, Hildreth JE, Derse CP, Klunk DA, Lichtenstein LM, Schleimer RP: IL-3 augments adhesiveness for endothelium and CD11b expression in human basophils but not neutrophils. J Immunol 1990;145:1832–1837.
19.
Gottsater A, Szelag B, Kangro M, Wroblewski M, Sundkvist G: Plasma adiponectin and serum advanced glycated end-products increase and plasma lipid concentrations decrease with increasing duration of type 2 diabetes. Eur J Endocrinol 2004;151:361–366.
20.
Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992;267:5133–5138.
21.
Liu Y, Liang C, Liu X, Liao B, Pan X, Ren Y, Fan M, Li M, He Z, Wu J, Wu Z: AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-kappaB pathways. Atherosclerosis 2010;208:34–42.
22.
Sun C, Liang C, Ren Y, Zhen Y, He Z, Wang H, Tan H, Pan X, Wu Z: Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Res Cardiol 2009;104:42–49.
23.
Vlassara H: The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001;17:436–443.
24.
Horiuchi S, Higashi T, Ikeda K, Saishoji T, Jinnouchi Y, Sano H, Shibayama R, Sakamoto T, Araki N: Advanced glycation end products and their recognition by macrophage and macrophage-derived cells. Diabetes 1996;45(suppl 3):S73–S76.
25.
Peleg AY, Weerarathna T, McCarthy JS, Davis TM: Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2007;23:3–13.
26.
Joshi N, Caputo GM, Weitekamp MR, Karchmer AW: Infections in patients with diabetes mellitus. N Engl J Med 1999;341:1906–1912.
27.
Otton R, Soriano FG, Verlengia R, Curi R: Diabetes induces apoptosis in lymphocytes. J Endocrinol 2004;182:145–156.
28.
Tedgui A, Mallat Z: Apoptosis as a determinant of atherothrombosis. Thromb Haemost 2001;86:420–426.
29.
Ferhani N, Letuve S, Kozhich A, Thibaudeau O, Grandsaigne M, Maret M, Dombret MC, Sims GP, Kolbeck R, Coyle AJ, Aubier M, Pretolani M: Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:917–927.
30.
Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M: The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol 2006;19:1437–1445.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.